Minimally invasive versus open pancreatoduodenectomy in benign, premalignant, and malignant disease

Deniece Riviere; Peter B van den Boezem; Marc G Besselink; Cornelis Jhm van Laarhoven; David A Kooby; Charles M Vollmer; Brian R Davidson; Kurinchi Selvan Gurusamy

doi:10.1002/14651858.CD014017

Minimally invasive versus open pancreatoduodenectomy in benign, premalignant, and malignant disease

Cochrane Database Syst Rev. 2024 Jul 26;7(7):CD014017. doi: 10.1002/14651858.CD014017.

Authors

Deniece Riviere¹, Peter B van den Boezem², Marc G Besselink³, Cornelis Jhm van Laarhoven², David A Kooby⁴, Charles M Vollmer⁵, Brian R Davidson⁶, Kurinchi Selvan Gurusamy⁶

Affiliations

¹ Department of Medical Imaging, Radboud University Medical Center Nijmegen, Nijmegen, Netherlands.
² Department of Surgery, Radboud University Medical Center, Nijmegen, Netherlands.
³ Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
⁴ Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA.
⁵ Department of Gastrointestinal Surgery, University of Pennsylvania, Philadelphia, PA, USA.
⁶ Division of Surgery and Interventional Science, University College London, London, UK.

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of laparoscopic or robot-assisted pancreatoduodenectomy versus open pancreatoduodenectomy for people with benign, premalignant, and malignant disease.

MeSH terms

Humans
Laparoscopy* / adverse effects
Laparoscopy* / methods
Pancreatic Diseases / surgery
Pancreatic Neoplasms* / surgery
Pancreaticoduodenectomy* / adverse effects
Pancreaticoduodenectomy* / methods
Precancerous Conditions* / surgery
Randomized Controlled Trials as Topic
Robotic Surgical Procedures / adverse effects
Robotic Surgical Procedures / methods
Systematic Reviews as Topic